Navigation Links
ESMO 2012 Congress: Program preview
Date:9/4/2012

The final program of the ESMO 2012 Congress including all late-breaking abstract titles is online! http://www.esmo.org/events/vienna-2012-congress/program.html

The ESMO 2012 Congress looks to be one of the best in this year's oncology scenario, possibly a "practice-changing" congress: results from long awaited trials; new drug approvals or new indications for drugs already used in other settings; randomized phase III studies and trials in earlier phases of research, which indicate new signals of activity or bring new concepts for future research; also studies that seem disappointing if you simply look at numbers, but with beautiful scientific rationale, for which expert and lively discussions are expected on how to move on with research agenda priorities or in the practice arena upon non-validation of the original hypothesis

Watch out for thrilling results in the following areas and make sure you don't miss the expert discussions on the future of treatments for these diseases:

  • Lung cancer: crizotinib, a new ready-to-use targeted drug for a molecularly defined sub-set of patients based on the results of the first phase III study in such setting; study results offering for the first time directions on how to treat patients with a certain EGFR mutation; first-time positive results for sorafenib treatment based on biomarker analysis in heavily pre-treated patients
  • Renal cell carcinoma: new drug in the jungle of available treatments for RCC; different strategies to target the disease
  • Melanoma: combination of MEK and BRAF inhibitors proves clinically meaningful to delay resistance
  • Early and metastatic breast cancer: answers on standard duration of adjuvant treatment for HER2-positive early breast cancer; what's behind low breast conserving surgery in the context of clinical trials;
  • Gastrointestinal tumors: what could be the role of targeted treatments for esophageal cancer progressing after chemo; combination of therapies for gastric cancer in a specific ethnicity; new targets and results of clinical studies with targeted agents in hepatocellular carcinoma
  • CNS tumors: new predictive marker identified for anti-angiogenic treatment
  • Ovarian cancer: drug combination opportunity for platinum-resistant recurrent ovarian cancer
  • Sarcoma: awaited results of a long-term academic study evaluating classical chemotherapy agents in a fashion of single versus combination first-line treatment for advanced soft tissue sarcoma

    Just to mention a few

    Not to be missed are also presentations and discussions on:

  • The economic direct and indirect burden of cancer in Europe
  • Health economics and drug cost in austerity
  • Patient awareness and understanding of personalized medicine
  • General public and oncology professional poor knowledge of risk factors for cancer
  • The need for prophylaxis of thrombosis in cancer patients
  • Future models of independent clinical research
  • Accessibility of cancer pain killers
  • Hereditary cancers and screening protocols Read the interview with Dr Judith Balmana, Chair of the ESMO 2012 Familial cancer track] http://www.esmo.org/fileadmin/media/pdf/2012/events/vienna/press/Balmana_FamilialCancers.pdf

    ESMO 2012 Press timetable

    These and other interesting topics will be presented during special sessions for the media. The full text of the abstracts will be published on Monday, September 17 at 9:00 (CEST). Late-breaking abstracts and abstracts included in the press program will remain embargoed until their presentation at the Congress session or at the Press briefing, whichever comes first.

    Wednesday, 26 September, 10:00-11:00, Presseclub Concordia
    German Press Conference: Congress program highlights with specific reference to topics for the Austrian media. Featuring a.o. the Austrian Minister of Health

    Friday, 28 September, 11:30-12:30, ESMO Press Conference Room, ACV
    Opening press conference: ESMO's President welcome; Congress program highlights; Appointments for journalists; The economic direct and indirect burden of cancer in Europe

    Saturday, 29 September, 8:15-9:00, ESMO Press Conference Room, ACV
    Press briefing Day 1: Melanoma; Lung cancer; Gastrointestinal tumors

    Saturday, 29 September, 11:00-12:00 (TBC), ESMO Press Conference Room, ACV
    Press conference: What personalized medicine practically means for patients

    Sunday, 30 September, 8:15-9:00, ESMO Press Conference Room, ACV
    Press briefing Day 2: Breast cancer; Lung cancer; Promising new weapons in the fight against cancer

    Sunday, 30 September, 12:00-13:00, ESMO Press Conference Room, ACV
    Press Conference: Prevention and screening What people know about it

    Monday, 1 October, 8:15-9:00, ESMO Press Conference Room, ACV
    Press briefing Day 3: Breast cancer; Renal cell carcinoma; Gastrointestinal tumors

    Tuesday, 2 October, 9:30-10:30, ESMO Press Conference Room, ACV
    Closing press conference: Congress highlights; Top practice changes to make after ESMO 2012; Cancer care in austerity times: how to improve equal access to quality cancer care across Europe


    '/>"/>


  • Contact: Vanessa Pavinato
    media@esmo.org
    European Society for Medical Oncology
    Source:Eurekalert

    Related medicine news :

    1. Wayne State researchers say adolescent smoking prevention programs still critical
    2. Germany launches a €16 million epigenome program
    3. Cleveland Clinic Florida receives approval for transplant programs at Weston Facilities
    4. Adolescents in substance abuse programs report using others med marijuana
    5. Implementing a therapeutic hypothermia program for post-cardiac arrest in acute care hospitals
    6. New FDA program adds to tools to curb opiod abuse in United States
    7. Surgical patient safety program lowers SSIs by one-third following colorectal operations
    8. ASH launches multi-million-dollar grant program to support critical blood disease research
    9. A nursing program shows promise for reducing deaths from chronic illnesses
    10. Scientists find new way to induce programmed cell death, or apoptosis
    11. Gallo Research Center to lead $15 million US Army-funded national research program
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/13/2017)... Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD ... dose required and providing a CBD form that can be easily incorporated into liquid ...
    (Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The Visiting ... Day Market. Featuring a collection of specialty vendors and unique items from across the ... and quality-focused health and wellness services offered by the VNA. The boutique will ...
    (Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
    (Date:10/12/2017)... ... ... Planet Fitness, one of the largest and fastest growing franchisors and operators ... location in Covington, LA at 401 N. U.S. Highway 190, in January of 2018. ... in the Holiday Square shopping center. Its location allows it to serve both Covington ...
    (Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
    Breaking Medicine News(10 mins):
    (Date:10/12/2017)... , Oct. 12, 2017 AVACEN Medical ... the company with their  2017 New Product Innovation Award ... on extensive primary and secondary medical device market research by ... through its first-to-market OTC, drug-free pain relief product, the AVACEN ... approach to treating fibromyalgia widespread pain. ...
    (Date:10/12/2017)... -- West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today announced that it will release third-quarter 2017 ... 26, 2017, and will follow with a conference call ... a.m. Eastern Time. To participate on the call, please ... is 94093362. A ...
    (Date:10/11/2017)...  Caris Life Sciences ® , a leading innovator ... precision medicine, today announced that St. Jude Medical Center,s ... (POA) as its 17 th member. Through participation ... Cancer Institute will help develop standards of care and ... making cancer treatment more precise and effective. ...
    Breaking Medicine Technology: